GURUFOCUS.COM » STOCK LIST » USA » NYSE » Biohaven Ltd (NYSE:BHVN) » Definitions » 3-Year EPS without NRI Growth Rate
Switch to:

Biohaven (NYSE:BHVN) 3-Year EPS without NRI Growth Rate

: 0.00% (As of Sep. 2022)
View and export this data going back to 2022. Start your Free Trial

Biohaven's EPS without NRI for the three months ended in Sep. 2022 was $-1.75.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Competitive Comparison

For the Biotechnology subindustry, Biohaven's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven 3-Year EPS without NRI Growth Rate Distribution

For the Biotechnology industry and Healthcare sector, Biohaven's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Biohaven's 3-Year EPS without NRI Growth Rate falls in comparison to its industry or sector. The grey bar indicates the 3-Year EPS without NRI Growth Rate's extreme value range as defined by GuruFocus.



Biohaven 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Biohaven  (NYSE:BHVN) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Biohaven 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Biohaven's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven (NYSE:BHVN) Business Description

Biohaven logo
Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
215 Church Street, New Haven, CT, USA, 06510
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.
Executives
George C. Clark officer: VP, Chief Accounting Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Robert J Hugin director C/O THE MEDICINES CO, 8 CAMPUS DR, PARSIPPANY NJ 07054
Michael Thomas Heffernan director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Julia P Gregory director 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX 77381
Gregory Bailey director 4 A CHESHAM STREET, LONDON X0 SW1X8DT
Kimberly Gentile officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
John W Childs director 111 HUNTINGTON AVENUE, SUITE 2900, BOSTON MA 02199
Vlad Coric director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Irina Antonijevic director 215 CHURCH STREET, NEW HAVEN CT 06510
Matthew Buten officer: Chief Financial Officer 215 CHURCH STREET, NEW HAVEN CT 06510
Kishan Mehta director 540 WEST 49TH STREET, UNIT# PH1N, NEW YORK NY 10019
Biohaven Pharmaceutical Holding Co Ltd. 10 percent owner 215 CHURCH STREET, NEW HAVEN CT 06510
Bruce Car officer: Chief Scientific Officer AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139

Biohaven (NYSE:BHVN) Headlines

Other Sources